Chelsea Krotje

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

Shahin Lockman, Sean S. Brummel, Lauren Ziemba et al. · The Lancet · 2021 · 160 citations · Full text

Medicine, Obstetrics, Pharmacotherapy +16

Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial

Lameck Chinula, Lauren Ziemba, Sean S. Brummel et al. · The Lancet HIV · 2023 · 29 citations · Full text

Medicine, Maternal Health, Obstetrics +16

Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1–2 dose-confirmation study

Kristina M. Brooks, Jennifer J. Kiser, Lauren Ziemba et al. · The Lancet HIV · 2023 · 12 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +17

Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate–Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum

Risa M. Hoffman, Sean S. Brummel, Lauren Ziemba et al. · Clinical Infectious Diseases · 2024 · 12 citations · Full text

Public Health, Maternal Health, Obstetrics +17

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

Carolyn Bolton‐Moore, Kristin Baltrusaitis, Brookie M. Best et al. · The Lancet HIV · 2025 · 11 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17